Glusa-D Tablet is a combination pharmaceutical formulation containing Diacerein 50 mg, Glucosamine Sulfate Potassium Chloride 750 mg, and Methyl Sulfonyl Methane (MSM) 250 mg, indicated primarily for the management of osteoarthritis and related degenerative joint disorders. Diacerein is an anthraquinone derivative that exhibits anti-inflammatory and chondroprotective properties by inhibiting interleukin-1 beta, thereby reducing cartilage degradation and promoting joint function. Glucosamine Sulfate Potassium Chloride serves as a key substrate in the biosynthesis of glycosaminoglycans and proteoglycans, essential components of cartilage matrix, facilitating repair and maintenance of articular cartilage. Methyl Sulfonyl Methane, an organosulfur compound, contributes to anti-inflammatory effects and supports connective tissue health by enhancing collagen synthesis and reducing oxidative stress. The synergistic action of these three active ingredients helps alleviate joint pain, improve mobility, and slow the progression of cartilage deterioration in patients with osteoarthritis. Glusa-D Tablet is generally well-tolerated; however, it should be used under medical supervision, especially in patients with hepatic or renal impairment. Regular monitoring is advised to assess therapeutic response and detect any adverse effects. This combination therapy offers a comprehensive approach to managing symptoms and improving quality of life in individuals with degenerative joint conditions.